Management of Superficial Vein Thrombosis

Anticoagulation Therapy

• The American College of Chest Physicians recommends 3 months of therapeutic anticoagulation for SVT near the saphenofemoral junction, with a strength of evidence rated as high 1
• For SVT with concurrent DVT, the American College of Chest Physicians recommends a minimum of 3 months of anticoagulation 1
• Prophylactic-dose fondaparinux 2.5 mg daily or low-molecular-weight heparin (LMWH) is recommended as initial treatment for extensive superficial vein thrombosis (SVT), with fondaparinux preferred over LMWH, based on strong evidence from clinical trials 1
• The following treatment durations are recommended:

• Anticoagulation is recommended for at least 3 months or as long as the catheter is in place for catheter-associated SVT, and for cancer patients, anticoagulation for at least 3 months or as long as cancer is active/under treatment, as recommended by the National Comprehensive Cancer Network and the American College of Chest Physicians 3, 4, 1, 5

Symptomatic Treatment and Prevention

• For SVT on the hand less than 1 cm in size, symptomatic treatment with warm compresses, nonsteroidal anti-inflammatory drugs (NSAIDs), and elevation of the affected limb is recommended, with monitoring for progression 3
• Topical non-steroidal anti-inflammatory drugs (NSAIDs) applied locally to the affected area, along with warm compresses and elevation of the affected limb, are recommended for symptomatic treatment 6
• Elastic compression stockings (20-30 mmHg gradient) are recommended for symptomatic relief, as suggested by the American Academy of Family Physicians 7
• Early mobilization rather than bed rest is recommended for patients with SVT 8
• Compression bandages or sleeves may be considered for symptom relief if post-thrombotic syndrome develops in patients with upper extremity Deep Vein Thrombosis (DVT) 8
• Early mobilization after surgery, proper IV catheter care and placement techniques, regular inspection of IV sites, removal of IV catheters as soon as clinically appropriate, and consideration of prophylactic measures in high-risk patients can help prevent post-operative phlebitis 1, 9, 10

Special Populations

• Cancer patients may require closer monitoring and potentially prolonged anticoagulation, as recommended by the NCCN guidelines, with a strength of evidence rated as moderate 3
• Pregnant women with proven SVT should be treated with Low Molecular Weight Heparin (LMWH) over no anticoagulation, as recommended by the American Society of Hematology, with a conditional recommendation 6
• Young patients with upper extremity DVT should be investigated for underlying causes, including screening for thrombophilia, especially if there's a family history of thrombotic events 1, 8

Diagnosis and Follow-up

• Comprehensive duplex ultrasound should assess both superficial and deep venous systems to evaluate for thrombus extension, as recommended by the American Heart Association and the American College of Cardiology 3, 11
• Baseline laboratory testing, including CBC with platelet count, renal and hepatic function panel, aPTT, and PT/INR, is recommended for patients with SVT, with monitoring of hemoglobin, hematocrit, and platelet count every 2-3 days for the first 14 days while inpatient, then every 2 weeks thereafter 3
• Follow-up ultrasound is recommended to evaluate for thrombus progression, with a suggested follow-up in 7-10 days, and continuation of anticoagulation for the full recommended duration even if symptoms improve, as recommended by the NCCN and the American College of Chest Physicians, with a strength of evidence rated as moderate 4, 3, 8, 5